Brand Name
Oxervate
Generic Name
Cenegermin-Bkbj
View Brand Information FDA approval date: November 26, 2018
Classification: Recombinant Human Nerve Growth Factor
Form: Kit, Solution
What is Oxervate (Cenegermin-Bkbj)?
OXERVATE ® ophthalmic solution.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Evaluation of Changes in Corneal Stromal Thickness Using Anterior Segment OCT Following Treatment of Neurotrophic Ulcers With Oxervate
Summary: Neurotrophic keratitis (NK) is a condition where the cornea, or clear outer covering of the eye, has reduced sensation due to a variety of reasons. In more advanced cases of NK, the cornea can develop an area of thinning called an ulcer. The purpose of this research is to find out if Oxervate (cenegermin-bkbj 0.002%) an FDA-approved treatment for neurotrophic corneal ulcers leads to an increase in...